Summary
- Profile Type
- Technology request
- POD Reference
- TRGB20260811012
- Term of Validity
- 11 August 2026 - 11 August 2027
- Company's Country
- United Kingdom
- Type of partnership
- Commercial agreement with technical assistance
- Research and development cooperation agreement
- Targeted Countries
- All countries
General information
- Short Summary
- We are a UK biotech developing genome-inactivated Bacteria-Like Particles (BLiPs) using proprietary bioinformatics and synthetic biology to create non-replicative bacteria that retain native surface antigens. Our lead programmes include a nasal vaccine for recurrent UTIs and immune trainers for respiratory diseases. We offer genome inactivation services and seek R&D partners with validated in vitro and/or in vivo UTI or respiratory infection models.
- Full Description
-
We are a UK-based SME developing a novel immunomodulatory platform based on programmable, genome-inactivated Bacteria-Like Particles (BLiPs). Using proprietary bioinformatics and synthetic biology, the company generates fully inactivated, non-replicative bacterial cells that retain native surface antigens and pathogen-associated molecular patterns (PAMPs), enabling potent immune stimulation with an enhanced safety profile. The BLiP platform overcomes key limitations of conventional bacterial inactivation methods and subunit vaccine approaches while providing a versatile platform for prophylactic and immunomodulatory applications.
The company is advancing two lead programmes. The first is an intranasal prophylactic vaccine against recurrent urinary tract infections (UTIs), targeting uropathogenic Escherichia coli (UPEC) to induce protective mucosal immunity. The second is a broad-spectrum innate immune trainer for respiratory diseases, designed to establish a pre-emptive antiviral state within the respiratory mucosa and provide pathogen-agnostic protection against emerging and seasonal respiratory viruses.
In parallel, we offer genome inactivation services for custom bacterial targets, supporting the development of safe bacterial products and research tools.
We seek international R&D collaborations with academic, CRO, and industrial partners possessing established in vitro and/or in vivo UTI models, human airway or immune models, and respiratory infection challenge models. Collaborations will involve joint study design, evaluation of BLiP-based candidates in partner models, and shared data generation to validate efficacy, mechanism of action, and translational potential.
The desired outcome is to establish robust preclinical proof-of-concept for both lead programmes while demonstrating the broader applicability of the BLiP platform. - Advantages and Innovations
-
• Genome inactivation: Precise molecular inactivation of the bacterial genome without heat or chemicals, ensuring complete safety and eliminating replication risk.
• Full antigen preservation: Retains the entire native surface antigen profile, unlike subunit or killed vaccines, enabling broader and more authentic immune responses.
• Live-vaccine-like efficacy with inactivated safety: Combines high immunogenicity with the safety, stability, and regulatory advantages of inactivated products.
• Programmable, platform technology: Adaptable across bacterial species and indications, enabling rapid development and broad applicability. - Technical Specification or Expertise Sought
-
• Validated preclinical models: Access to established in vitro and/or in vivo UTI, human airway, immune, and respiratory viral challenge models to evaluate BLiP-based candidates.
• Preclinical immunology expertise: Capability to assess immunogenicity, mucosal immunity, trained immunity, and protective efficacy following intranasal administration.
• Microbiology, virology, and systems immunology: Expertise in uropathogenic E. coli, respiratory viruses, host–pathogen interactions, and multi-omics, epigenetic, and cytokine profiling to characterise mechanism of action and immune responses. - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- Goal 9: Industry, Innovation and Infrastructure
- IPR status
- Secret know-how
Partner Sought
- Expected Role of a Partner
- We seek international academic, CRO, and industrial R&D partners with expertise in UTI research, respiratory virology, and mucosal immunology. Partners should provide validated in vitro and/or in vivo UTI, airway, immune, or respiratory viral challenge models to support preclinical evaluation of BLiP-based vaccine and innate immune trainer candidates, including immunogenicity, mechanism-of-action, and efficacy studies. Collaborations will involve joint study design, data generation, and analysis to establish preclinical proof-of-concept, supporting further co-development, IP expansion, regulatory engagement, and investment activities.
- Type and Size of Partner
- Big company
- R&D Institution
- SME 50 - 249
- Type of partnership
- Commercial agreement with technical assistance
- Research and development cooperation agreement
Dissemination
- Technology keywords
- 06001006 - Human vaccines
- 06001002 - Clinical Research, Trials
- 06001012 - Medical Research
- Market keywords
- 05003005 - Drug delivery and other equipment
- 05003006 - Other therapeutic (including defibrillators)
- 05003001 - Therapeutic services
- Targeted countries
- All countries